|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM204098386 |
| 003 |
DE-627 |
| 005 |
20231223231403.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.11.001
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0680.xml
|
| 035 |
|
|
|a (DE-627)NLM204098386
|
| 035 |
|
|
|a (NLM)21130688
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Sacchi, Alessandra
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The basal activation state of DC subsets correlates with anti-HCV treatment outcome in HCV/HIV co-infected patients
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 21.03.2011
|
| 500 |
|
|
|a Date Revised 01.12.2018
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a In this work we evaluated plasmacytoid (pDC) and myeloid dendritic (mDC) cells activation before and during anti-HCV treatment in HCV+/HIV+ individuals. HCV+/HIV+ patients received Peg-IFN-α2b subcutaneously for 28 days, followed by oral weight-based ribavirin. DCs activation was evaluated by flow cytometry. Baseline pDC CD80 and CD86 expression was correlated with HIV, but not with HCV viral load. A transient decrease of HIV RNA was found not associated with DC activation. When patients were grouped according to early/sustained virological response (EVR/SVR) to anti-HCV treatment, baseline pDC CD80 and CD86 expression was higher in non-EVR and non-SVR compared to EVR and SVR. Moreover, in responder patients CD80 and CD86 were upregulated by IFN-α. Our data suggest a correlation between DCs activation and response to therapy. These findings could be helpful to better understand the mediators of IFN-α action in HCV+/HIV+ patients and to explore possible exploitation of this knowledge to improve therapeutic response
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a Interferon alpha-2
|2 NLM
|
| 650 |
|
7 |
|a Interferon-alpha
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Proteins
|2 NLM
|
| 650 |
|
7 |
|a Polyethylene Glycols
|2 NLM
|
| 650 |
|
7 |
|a 3WJQ0SDW1A
|2 NLM
|
| 650 |
|
7 |
|a Ribavirin
|2 NLM
|
| 650 |
|
7 |
|a 49717AWG6K
|2 NLM
|
| 650 |
|
7 |
|a peginterferon alfa-2b
|2 NLM
|
| 650 |
|
7 |
|a G8RGG88B68
|2 NLM
|
| 700 |
1 |
|
|a Agrati, Chiara
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a D'Offizi, Gianpiero
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vlassi, Chrysoula
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rozera, Gabriella
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Abbate, Isabella
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Capobianchi, Maria Rosaria
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Martini, Federico
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 138(2011), 2 vom: 01. Feb., Seite 178-86
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:138
|g year:2011
|g number:2
|g day:01
|g month:02
|g pages:178-86
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.11.001
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 138
|j 2011
|e 2
|b 01
|c 02
|h 178-86
|